David M. Knott’s Acadia Pharmaceuticals ACAD Stock Holding History

David M. Knott’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-550	Closed	-$21K	–	110
2017 Q3	$21K	Sell	550 -30,397	-98%	-$989K	0.01%	102
2017 Q2	$863K	Sell	30,947 -24,000	-44%	-$715K	0.36%	30
2017 Q1	$1.89M	Sell	54,947 -11,000	-17%	-$388K	0.91%	13
2016 Q4	$1.9M	Buy	65,947 +550	+0.8%	+$14.6K	0.96%	11
2016 Q3	$2.08M	Sell	65,397 -200	-0.3%	-$6.78K	1.07%	10
2016 Q2	$2.13M	Buy	65,597 +60,097	+1,093%	+$2.01M	0.49%	27
2016 Q1	$154K	Buy	+5,500	New	+$120K	0.04%	58
2015 Q2	–	Sell	-30,800	Closed	-$1M	–	85
2015 Q1	$1M	Sell	30,800 -15,000	-33%	-$516K	0.22%	40
2014 Q4	$1.45M	Hold	45,800	–	–	0.34%	37
2014 Q3	$1.13M	Hold	45,800	–	–	0.22%	43
2014 Q2	$1.03M	Hold	45,800	–	–	0.19%	41
2014 Q1	$1.11M	Hold	45,800	–	–	0.21%	41
2013 Q4	$1.14M	Sell	45,800 -4,200	-8%	-$99.1K	0.23%	40
2013 Q3	$1.37M	Hold	50,000	–	–	0.26%	42
2013 Q2	$908K	Buy	+50,000	New	+$689K	0.19%	43

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

David M. Knott's ACAD Position: Q4 2017 in Review

David M. Knott sold out of Acadia Pharmaceuticals (ACAD) in Q4 2017, closing a stake of 550 shares — an estimated $21K sold.

David M. Knott first reported a position in ACAD in Q2 2013 and held it in 15 quarters. The position peaked at $2.13M in Q2 2016. 210 funds tracked by Wall St. Rank hold ACAD as of Q4 2017.

David M. Knott reported no remaining Acadia Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
David M. Knott sold 550 Acadia Pharmaceuticals shares in Q4 2017, an estimated $21K.
David M. Knott first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 15 quarters.
David M. Knott's Acadia Pharmaceuticals position peaked at $2.13M in Q2 2016.
210 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2017.

Based on David M. Knott's 13F filing for Q4 2017, filed 13 Feb 2018.